According to a recently published article in the journal Cancer Research, a new study from the Center for Individualized Medicine has found tumor sequencing of several different lung cancers and their surrounding tissue complicates the prevailing theory of linear lung cancer progression and offers new insights for management of this deadly cancer. Sequencing results provide, for the first time, strong molecular evidence of progression from phenotypically indolent components to more aggressive disease and also show that both components can progress independently, even if they arise from the same precursor, according to the study.
"This study sheds light on potential changes in our understanding of both the molecular pathogenesis and best treatment of lung adenocarcinoma," says George Vasmatzis, Ph.D., co-director of the Biomarker Discovery Program. "The heterogeneity of lung cancer tells us repeatedly that the natural history of tumors and the roads to progression vary among cases, and multiple models are possible in certain cancers."
Future studies of lung cancer genomics and tumor progression are underway from Vasmatzis' team in the Biomarker Discovery Program. Their goal is to develop a series of predictive biomarkers that can help patients and physicians separate potentially aggressive and life-threatening lung cancers from indolent ones based on the molecular signatures found within the individual patient's tissue.
Full Article Featured on Advanced Healthcare Network.
Tags: cancer, center for individualized medicine, DNA, DNA Sequencing, dna test, DNA Testing, gene sequencing, Genetics, genome, genome science, Genome Sequencing, genomic medicine, genomics, individualized medicine, Lung Cancer, mayo clinic, personal genomics, personalized care, personalized medicine, pharmacogenomics, predictive medicine, Uncategorized, whole genome sequencing